Objective: To observe the effects of electroacupuncture (EA) on depressive-like behavior, synaptic plasticity and 5-HTT protein expression of hippocampal CA1 region in the WKY model rats. Methods In this experiment, 10 male Wistar rats were selected as the normal group (Control), and 30 male WKY rats were randomly divided into model group, electroacupuncture group (EA) and sham needle group (Sham EA) . Behavioral testing was performed by the Sour Water Preference Experiment (SPT), the Open Field Experiment (OFT), and the Forced Swimming Experiment (FST) . The electrophysiological field potential experiment was used to detect the effect of electroacupuncture on LTP in the hippocampal CA1 region of rats with depression, which is the effect on synaptic plasticity. The expression of 5-HTT protein in hippocampal CA1 region was detected by Western blot. Results In the SPT, compared to the Control group, the sucrose solution intake was significantly reduced in the Model group (P ＜ 0.01) . It was improved after EA treatment compared to Sham EA group (P ＜ 0.05) . In the OFT, compared with the Control group, the center time, total move time, center distance, total distance, rearing and grooming incidents were all decreased in the Model group. Compared with the Model group, the center time and total move time in the EA group increased significantly after 3 weeks of treatment (P ＜0.05) . In the FST, duration of immobility was significantly (P ＜ 0.05) longer in the Model group comparing with the Control group. Compared with Sham EA group and Model group, the immobile time of EA group was significantly shorter (P ＜ 0.05) . Compared with the Control group, the fEPSP slope of the Model group was significantly shorter (P ＜ 0.001) .Compared with the Sham EA group, the fEPSP slope of the EA group increased significantly (P ＜ 0.001) . And the LTP of Sham EA and Model groups induced failure in hippocampal CA1 region, the LTP induction was successful after EA treatment. Compared with the Control group, the expression of 5-HTT protein was significantly increased (P＜0.001) .Compared with Sham EA group, the expression of 5-HTT protein in EA group decreased (P ＜ 0.001) . Conclusion EA could alleviate depression-like behaviors in depression model rats and reverse the impairment of hippocampus synaptic plasticity by decrease the over-expression of 5-HTT protein in hippocampal CA1 region. It may be one of the mechanisms of EA on depression.

Objective To explore the effect and possible pharmacological mechanism of Bufei Tongbi Decoction in the treatment of systemic lupus erythematosus interstitial lung disease (SLE-ILD).Methods The effective components and related targets of Bufei Tongbi Decoction were obtained using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and Uniprot database. Key genes for SLE-ILD were screened based on DrugBank,DisGeNET,GeneCards,PharmGKB,OMIM,and GEO databases. Using Cytoscape software,a drug active ingredient-target-disease relationship network diagram was constructed to obtain the effective active ingredients and possible mechanisms of action of Bufei Tongbi Decoction in the treatment of SLE-ILD. Gene ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were used to reveal related target genes and pathway functions. Taking C57BL/6 mice as normal group,MRL/lpr mice were injected with bleomycin 5mg/kg in the nasal cavity. According to the random number table method,the mice were divided into model group,Bufei Tongbi Decoction low-dose group (10.4 g/(kg·d)),Bufei Tongbi Decoction medium-dose group (20.8 g/(kg·d)),Bufei Tongbi Decoction high-dose group (41.6 g/(kg·d)) and prednisone group (3 mg/(kg·d)). The intervention lasted for 28 days. Hematein eosin and Masson staining were used to observe the pathological changes of mouse lung tissue,the expressions of transforming growth factor-β1 (TGF-β1) and collagen type Ⅲ (Col-Ⅲ) in lung tissue were detected by immunohistochemistry,and the expressions of interleukin-1β(IL-1β),interleukin-10 (IL-10) and interleukin-17 (IL-17) in serum were detected by ELISA. The mRNA expressions of matrix metallopeptidase 1(MMP-1),hypoxia inducible factor-1α(HIF-1α),retinoid-related orphan receptor γt (RORγt ) and forkhead box P3 (FOXP3) in lung tissue were analyzed by RT-PCR,the protein expressions of HIF-1α and MMP-1 in lung tissue were detected by Western blotting,and the expressions of T helper 17 cells (Th17) and regulatory T cells (Treg cells) in blood were detected by cytometry.Results A total of 163 effective ingredients,259 targets,1729 SLE-ILD disease targets,958 SLE-ILD differential genes and 40 drug-disease interaction targets were obtained by screening. GO functional enrichment and KEGG pathway enrichment showed that IL-17 signaling pathway activated by IL-1β and MMP-1,and Th17 cell differentiation activated by IL-1β and HIF-1α were the main pathways. Animal experiments showed that Bufei Tongbi Decoction could effectively improve the degree of lung interstitial lesion and reduce the expressions of TGF-β1 and Col-Ⅲ in SLE-ILD mice (P<0.01). The expressions of IL-1β,HIF-1α and IL-17 were decreased (P<0.01). Medium and high doses of Bufei Tongbi Decoction decreased the expressions of MMP-1 and RORγt mRNA (P<0.01),and increased the expressions of IL-10 and FOXP3 mRNA (P<0.01). Bufei Tongbi Decoction could reduce the proportion of Th17 cells,increase the proportion of Treg cells,downregulate the balance of Th17/Treg (P<0.05),and improve the immune disorder. Conclusion Bufei Tongbi Decoction has the characteristics of multi-target and multi-pathway in treating SLE-ILD,and its mechanism may be related to the regulation of Th17/Treg cell balance.

Metabolic regulation has been proven to play a critical role in T cell antitumor immunity. However, cholesterol metabolism as a key component of this regulation remains largely unexplored. Herein, we found that the low-density lipoprotein receptor (LDLR), which has been previously identified as a transporter for cholesterol, plays a pivotal role in regulating CD8